AIMS: To demonstrate the safety, performance and efficacy of the Endeavor Resolute stent in the treatment of patients with multiple-vessel as well as single-vessel coronary artery disease but where only one lesion per patient was treated. METHODS AND RESULTS: 130 patients were treated with the Endeavor Resolute stent. Of these patients, 30 consented to a 4 month follow-up evaluation by quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) measurements, and 100 consented to a 9 month follow-up evaluation by QCA. Only lesions with diameter stenoses > 50% and with lengths > 14 mm and < 27 mm in vessels with reference diameters > 2.5 mm to < 3.5 mm were included. The device success rate as 99.2%, and the procedure success rate was 96.2%. The mean lesion length was 15.56+/-6.27 mm. The overall 30 day incidence of major adverse cardiac events (MACE) was 3.3%, which consisted entirely of 5 cases of peri-procedural non-Q-wave MI. The QCA and IVUS results at 4 months for the 30 patient subgroup showed in-stent late lumen loss was 0.12+/-0.26 mm, and in segment late lumen loss was 0.05+/-0.20 mm. CONCLUSIONS: The 4 month results in this subset of Endeavor Resolute patients demonstrated excellent procedural and device success when deployed in lesions up to 27 mm of length. The Endeavor Resolute stent, in this subset, was associated with a low in-stent late lumen loss and a minimal amount of neointimal hyperplastic in-growth.
AIMS: To demonstrate the safety, performance and efficacy of the Endeavor Resolute stent in the treatment of patients with multiple-vessel as well as single-vessel coronary artery disease but where only one lesion per patient was treated. METHODS AND RESULTS: 130 patients were treated with the Endeavor Resolute stent. Of these patients, 30 consented to a 4 month follow-up evaluation by quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) measurements, and 100 consented to a 9 month follow-up evaluation by QCA. Only lesions with diameter stenoses > 50% and with lengths > 14 mm and < 27 mm in vessels with reference diameters > 2.5 mm to < 3.5 mm were included. The device success rate as 99.2%, and the procedure success rate was 96.2%. The mean lesion length was 15.56+/-6.27 mm. The overall 30 day incidence of major adverse cardiac events (MACE) was 3.3%, which consisted entirely of 5 cases of peri-procedural non-Q-wave MI. The QCA and IVUS results at 4 months for the 30 patient subgroup showed in-stent late lumen loss was 0.12+/-0.26 mm, and in segment late lumen loss was 0.05+/-0.20 mm. CONCLUSIONS: The 4 month results in this subset of Endeavor Resolute patients demonstrated excellent procedural and device success when deployed in lesions up to 27 mm of length. The Endeavor Resolute stent, in this subset, was associated with a low in-stent late lumen loss and a minimal amount of neointimal hyperplastic in-growth.
Authors: M W Z Basalus; K Tandjung; K G van Houwelingen; M G Stoel; F H A F de Man; J W Louwerenburg; S A M Saïd; G C M Linssen; M A W J Kleijne; J van der Palen; J Huisman; P M J Verhorst; C von Birgelen Journal: Neth Heart J Date: 2010-08 Impact factor: 2.380
Authors: David E Kandzari; Pieter C Smits; Michael P Love; Ori Ben-Yehuda; Shmuel Banai; Simon D Robinson; Michael Jonas; Ran Kornowski; Rodrigo Bagur; Andres Iniguez; Haim Danenberg; Robert Feldman; Rajiv Jauhar; Harish Chandna; Manish Parikh; Gidon Y Perlman; Mercedes Balcells; Peter Markham; Melek Ozgu Ozan; Philippe Genereux; Elazer R Edelman; Martin B Leon; Gregg W Stone Journal: Circulation Date: 2017-08-09 Impact factor: 29.690
Authors: Juan Luis Gutiérrez-Chico; Robert Jan van Geuns; Evelyn Regar; Willem J van der Giessen; Henning Kelbæk; Kari Saunamäki; Javier Escaned; Nieves Gonzalo; Carlo di Mario; Francesco Borgia; Eveline Nüesch; Héctor M García-García; Sigmund Silber; Stephan Windecker; Patrick W Serruys Journal: Eur Heart J Date: 2011-06-09 Impact factor: 29.983